Mark R. Lackner

机构：Zen-Noh (Japan) · ORCID：0000-0002-6375-2037

发表论文 433 篇 · 总被引 8205 次 · h-index 46

代表论文

• Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers (2025 · npj Precision Oncology · 被引 18)
• Abstract 6093: IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets homologous-recombination-deficient and PARP inhibitor resistant breast and ovarian tumors (2023 · Cancer Research · 被引 15)
• Abstract 1644: Dual inhibition of MAT2A and PRMT5 delivers synergistic anti-tumor responses in preclinical models of MTAP-deleted cancer (2023 · Cancer Research · 被引 8)
• Abstract 2153: Cyclin E1 protein overexpression sensitizes ovarian cancer cells to ZN-c3, a novel, selective and oral bioavailable inhibitor of Wee1 (2023 · Cancer Research · 被引 4)
• Abstract 1628: A small-molecule inhibitor of WRN selectively kills MSI-H cancer cells and phenocopies WRN genetic defects (2023 · Cancer Research · 被引 3)
• 35P The selective WEE1 inhibitor azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I inhibitor-based antibody drug conjugates (2024 · Annals of Oncology · 被引 2)